Home / Market Research / Global Acute Myeloid Leukemia (AML) Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025

Global Acute Myeloid Leukemia (AML) Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025

Published: Sep 2017 | Published By: Acute Market Research

Acute Myeloid Leukemia (AML) Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global acute myeloid leukemia (AML) therapeutics market was valued at US$ 404.3 Mn in 2016, and is expected to reach US$ 1,025.9 Mn by 2025, expanding at a CAGR of 10.9% from 2017 to 2025.

Market Insights
Global acute myeloid leukemia (AML) therapeutics market will show significant market growth during forecast period due to some factors such as rising incidence of AML, higher number of unmet needs, expected launch of ideal molecules and extensive R&D activities in development of novel therapeutics. For the purpose of study AML therapeutics market is segmented on the basis of drug type such as pipeline drugs and chemotherapeutics drugs (Cytarabine, Anthracyclines, Etoposide and other). It is studied that currently, Cytarabine is preferably used in market due to its effectiveness and hence it is prime drug of chemotherapy regimens for induction therapy as well as post-remission therapy. Newly approved drugs such as gemtuzumab ozogamicin, Vyxeos, midostaurin expected to drive significant market growth during forecast period. In the base year 2016, North America is largest regional market for AML therapeutics, United States held largest market share in North America due to increase in prevalence of AML and developed healthcare infrastructure. It is estimated that Asia Pacific will show highest market growth during forecast period due to increasing healthcare awareness, developing healthcare infrastructure and increasing incidence of AML.

Market Competition Assessment:
The acute myeloid leukemia (AML) therapeutics market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Abbott Laboratories, Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical), Boehringer Ingelheim GmbH, Bristol Myers Squibb, Celegene Corporation, Cephalon Inc., Eisai Co. Ltd., Eli Lilly and Company, Genzyme Corporation (A subsidiary of Sanofi S.A.), Jazz Pharmaceuticals, Inc., Novartis AG, Pfizer Inc. and other.

Key Market Movements:
• Factors such as rising incidence of AML, extensive research and development activities, strong presence of pipeline molecules and upsurge in funding by the government for treatment are driving the growth of AML therapeutics market during forecast period.
• However, some factors such as lack of medication availability and poor diagnosis in some poor income countries may negatively impacting the growth of acute myeloid leukemia (AML) therapeutics market.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Snapshot
2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
2.3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share, by Geography, 2016 (Value %)

Chapter 3 Acute Myeloid Leukemia (AML) Therapeutics Market Analysis
3.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Acute Myeloid Leukemia (AML) Therapeutics
3.4 Global Epidemiology of Acute Myeloid Leukemia (AML)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Acute Myeloid Leukemia (AML) Therapeutics Market

Chapter 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
4.1 Overview
4.2 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
4.3 Top 3 Countries
4.4 Chemotherapy Drugs
4.4.1 Cytarabine
4.4.2 Anthracyclines
4.4.3 Etoposide
4.4.4 Other
4.5 Pipeline Drugs

Chapter 5 Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.2.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.3.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.5.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
6.3 Boehringer Ingelheim GmbH
6.4 Bristol Myers Squibb
6.5 Celegene Corporation
6.6 Cephalon Inc.
6.7 Eisai Co. Ltd.
6.8 Eli Lilly and Company
6.9 Genzyme Corporation (A subsidiary of Sanofi S.A.)
6.10 Jazz Pharmaceuticals, Inc.
6.11 Novartis AG
6.12 Pfizer Inc.

TABLE 1 Market Positioning of Key Players in Global Acute Myeloid Leukemia (AML) Therapeutics Market
TABLE 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 3 Top 3 Countries in Global Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 6 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 8 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 12 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 Abbott Laboratories: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Celegene Corporation: Company Snapshot (Business Description; FinanTABLE 1 Market Positioning of Key Players in Global Acute Myeloid Leukemia (AML) Therapeutics Market
TABLE 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 3 Top 3 Countries in Global Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 6 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 8 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 12 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 Abbott Laboratories: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Celegene Corporation: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Cephalon Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Genzyme Corporation (A subsidiary of Sanofi S.A.): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Jazz Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)cial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Cephalon Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Genzyme Corporation (A subsidiary of Sanofi S.A.): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Jazz Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

FIG. 1 Acute Myeloid Leukemia (AML) Therapeutics Market: Research Methodology
FIG. 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2016 (US$ Mn)
FIG. 3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2016
FIG. 6 Global Chemotherapy Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Acute Myeloid Leukemia (AML) Cytarabine Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Acute Myeloid Leukemia (AML) Anthracyclines Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Acute Myeloid Leukemia (AML) Etoposide Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Other Drugs in Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Pipeline Drugs in Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +